The JAMA Network today published the results from an Original Investigation on the Novavax COVID-19 vaccine.
In collaboration with the Department of Health and Human Services, Novavax researchers assessed the neutralizing antibody response to its COVID-19 vaccine (NVX-CoV2373) in a phase 3 clinical trial among adolescents from April 26 to June 5, 2021.
Protein-based COVID-19 Vaccine Over 79% Effective
Bird Flu Risk Rarely Detected in Humans
Is a bird flu pandemic really a risk to people in 2023? That is the question a group of researchers answered in an Early Release Original Publication posted today.
Since late 2021, the largest bird flu outbreak in history has impacted most countries.
In the U.S., the Centers for Disease Control and Prevention published a June 2023 Dispatch, Volume 29, Number 6, confirming a total of 39 states recently experienced outbreaks of highly pathogenic avian influenza A(H5N1) virus in birds from commercial poultry farms and backyard flocks.
HIV Vaccine Research Accelerates with Government Funding
While millions of people worldwide await the launch of an HIV vaccine, the U.S. government recently took action by committing to fund early-stage vaccine candidates.
On April 26, 2023, Uvax Bio, LLC announced that its HIV vaccine candidates had shown significantly improved immune response compared with current vaccine strategies.
Repeated Low-Level Red-Light Intervention Prevents Myopia in Children
RLRL effective for preventing myopia in children with premyopia, with up to a 54.1 percent reduction in incidence